In 2016, FAIRR initiated a three-year collaborative engagement to ask large food companies to end the nontherapeutic use of antibiotics important to human health…
FAIRR’s latest update on this engagement outlines how investors are stepping up to manage these risks and what progress has been made on the issue from corporate and policy communities.
Antibiotics use in livestock is a leading cause of rising antimicrobial resistance (AMR) in humans. The food industry is the largest consumer of antibiotics globally, and uses antibiotic drugs to prevent disease or promote growth in healthy farm animals rather than treat clinically ill animals.
AMR and antibiotics misuse presents a systemic risk to investor portfolios, including within the food, pharmaceutical, healthcare and insurance industries.
The UK government described the over-use of antibiotics as “excessive and inappropriate” in a report which found that drug-resistant infections could cost the world around US $100 trillion in lost output by 2050 – a cost that will come home to roost in a widely diversified portfolio.
Main contact: Jo Raven, Engagement Manager
See all the briefings that we have released on the overuse of antibiotics in protein supply chains.
FAIRR publishes company-level analysis arising from this engagement, available exclusively to our Investor Members.
The latest analysis was released in May 2019.